Showing 1 - 6 results of 6 for search 'Alan S. Wayne', query time: 0.03s Refine Results
  1. 1
    Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia

    Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia by Fabian Müller, Tyler Cunningham, Richard Beers, Tapan K. Bera, Alan S. Wayne, Ira Pastan

    Published 2018-05-01
    Get full text
    Article
  2. 2
    Biological roles and potential applications of immune cell-derived extracellular vesicles

    Biological roles and potential applications of immune cell-derived extracellular vesicles by Chuan Wen, Robert C. Seeger, Muller Fabbri, Larry Wang, Alan S. Wayne, Ambrose Y. Jong

    Published 2017-12-01
    Get full text
    Article
  3. 3
    Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.

    Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodie... by Hema Dave, Miriam R Anver, Donna O Butcher, Patrick Brown, Javed Khan, Alan S Wayne, Sivasubramanian Baskar, Christoph Rader

    Published 2012-01-01
    Get full text
    Article
  4. 4
    The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL

    The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL by Etai Adam, Hye Na Kim, Eun Ji Gang, Caitlin Schnair, Solomon Lee, Solah Lee, Sajad Khazal, Osanna Kosoyan, Marina Konopleva, Chintan Parekh, Deepa Bhojwani, Alan S. Wayne, Hisham Abdel-Azim, Nora Heisterkamp, Yong-Mi Kim

    Published 2017-09-01
    Get full text
    Article
  5. 5
    P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)

    P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL) by Armin Ghobadi, Ibrahim Aldoss, Shannon Maude, Alan S Wayne, Deepa Bhojwani, Ashish Bajel, Bhagirathbhai Dholaria, Rawan Faramand, Ryan Mattison, Michael Rettig, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen Mcnulty, Matthew Cooper, Jan Davidson-Moncada, Kenneth Jacobs, John Dipersio

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

    Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphom... by Anupam Verma, Yueh-Yun Chi, Jemily Malvar, Adam Lamble, Sonali Chaudhury, Archana Agarwal, Hong-Tao Li, Gangning Liang, Roy Leong, Patrick A. Brown, Joel Kaplan, Eric S. Schafer, Tamra Slone, Melinda Pauly, Bill H. Chang, Elliot Stieglitz, Alan S. Wayne, Nobuko Hijiya, Deepa Bhojwani

    Published 2024-01-01
    Get full text
    Article

Search Tools: